Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomized, open-label, phase 3 trial. This evidence concerns the gene MGMT and glioblastoma.